INVESTIGACIÓN PARA OTRA OPORTUNIDAD

Out-Back Fellowship 2026
List of centers

1. **Dana-Farber Cancer Institute, Boston, USA**
   Department of Cancer Immunology and Virology
   Judith Agudo, PhD,
   Judith_Agudo@dfci.harvard.edu
   Cancer immunology and resistance to immunotherapy.
   https://labs.dana-farber.org/agudolab/

2. **Temple University/Fox Chase Cancer Center, Philadelphia, USA**
   Molecular Oncology
   Pedro Torres Ayuso
   pedro.torres-ayuso@temple.edu
   Identification of mechanisms of tumorigenesis and treatment resistance in lung and head and neck cancers.
   https://www.foxchase.org/pedro-torres-ayuso
   https://medicine.temple.edu/directory/pedro-torres-ayuso-phd

3. **Temple University/Fox Chase Cancer Center, Philadelphia, USA**
   Gomez-Deza Lab, Department of Cancer and Cellular Biology
   Jorge Gomez-Deza
   jorge.gomez-deza@temple.edu
   Investigate how chemotherapy impacts neurons to reduce pain and improve treatment durability, using iPSCs, CRISPRi screens, and mouse models to identify protective strategies.
   http://www.gomezdezalab.com/

4. **Fox Chase Cancer Center, Philadelphia, USA**
   Cancer Signaling and Microenvironment
   Aitziber Buqué Martínez
   Aitziber.buquemartinez@fccc.edu
   Study of tumor microenvironment metabolism in the context of breast cancer.
   https://www.foxchase.org/news/2024-08-02-fox-chase-cancer-center-welcomes-aitziber-buque-martinez

5. **Amsterdam University Medical Centre, Amsterdam, Netherlands**
   Yvete van Kooyk group, Department Molecular Cell Biology and Inmunology
   Yvete van Kooyk / Postdoc: Sofía Ibáñez
   s.ibanezmolero@amsterdamumc.nl
   Study of immune interactions in cancer.
   https://www.amsterdamumc.org/en/research/researchers/yvette-van-kooyk.htm

6. **Aarhus University, Aarhus, Denmark**
   Molecular Biology and Genetics
   Xavier Bofill De Ros
   xbofill@mbg.au.dk
   Characterization of novel KI mouse models carrying hotspot mutations identified in patients in the DICER1 and DIS3L2 genes.
   https://www.au.dk/en/xbofill@mbg.au.dk/

7. **Universitätsklinikum Essen, Institut für Zellbiologie (Tumorforschung), Essen, Germany**
   Autophagy and cancer
   Silvia Vega-Rubín-de-Celis
   silvia.vegarubindecelis@uk-essen.de
   The Silvia Vega-Rubín-de- Celis group focuses on understanding the role of autophagy in cancer and exploring the use of autophagy modulating agents as potential therapeutic targets in tumors.
   https://www.uni-due.de/zmb/members/silvia-vega-rubin-de-celis.php

8. **Princess Margaret Cancer Center, Toronto, Canada**
   Cancer Clinical Research Unit (CCRU)
   Lillian Siu
   lillian.Siu@uhn.ca
   Developmental Therapeutics and Phase I Clinical Trials of Novel Agents.
   https://www.uhnresearch.ca/researcher/lillian-l-siu

9. **Institute of cancer research, London, UK**
   Glioma Team, Division of Cancer Biology
   Chris Jones
   chris.jones@icr.ac.uk
   Novel therapeutic approaches in paediatric diffuse midline and high-grade glioma.
   https://www.icr.ac.uk/research-and-discoveries/find-a-researcher/detail/prof-chris-jones

10. **Institute of cancer research, London, UK**

    Myeloma Biology and Therapeutics

    Charlotte Pawlyn

    charlotte.pawlyn@icr.ac.uk

    Myeloma Drug Resistance.

    https://www.icr.ac.uk/research-and-discoveries/icr-divisions/cancer-therapeutics/myeloma-biology-and-therapeutics

11. **UCL Cancer Institute - Great Ormond Hospital for Children, London, UK**

    Adoptive T cell immunotherapy for childhood tumours

    Karin Straathof

    k.straathof@ucl.ac.uk

    Advanced T cell engineering to develop effective CAR T cell therapies for childhood solid tumours including brain and non-brain tumours.

    https://www.cancergrandchallenges.org/dr-karin-straathof

12. **Institute of cancer research, London, UK**

    Targeted Therapy, Magnetic Resonance

    Kevin Harrington

    Kevin.Harrington@icr.ac.uk

    Professor Harrington's laboratory research group focuses on a number of themes at the interface between biologically-targeted agents and standard-of-care therapies, such as radiotherapy and chemotherapy.

    https://www.icr.ac.uk/research-and-discoveries/find-a-researcher/test-researcher-profile-detail/professor-kevin-harrington

13. **Institute of cancer research, London, UK**

    Translational Immunotherapy, Breast Cancer Immunology

    Alan Melcher

    Alan.Melcher@icr.ac.uk

    Alan Melcher's group combines a clinical practice in head and neck cancer and melanoma with laboratory and translational research focused on oncolytic viruses and immunotherapy for the treatment of cancer.

    https://www.icr.ac.uk/research-and-discoveries/find-a-researcher/test-researcher-profile-detail/professor-alan-melcher

14. **Memorial Sloan Kettering Cancer Center, New York, USA**

    Tow Center for Developmental Oncology

    Alex Kentsis

kentsisa@mskcc.org

Pediatric cancer.

https://www.mskcc.org/es/cancer-care/doctors/alex-kentsis#contact-and-location

15. **Memorial Sloan Kettering Cancer Center, New York, USA**

Asmin Tulpule Lab

Asmin Tulpule

tulpulea@mskcc.org

Biomolecular condensates in cancer with a focus on RAS/MAPK signaling and DNA repair.

https://www.mskcc.org/research-areas/labs/asmin-tulpule

16. **The Rockefeller University, New York, USA**

Cancer Biology

Sanford Simon

simon@mail.rockefeller.edu

The Simon laboratory focuses on single events—single proteins, single nuclear pores, single viruses, and single precisely defined cancers—to identify what is lost when using averages. Current work on childhood, adolescent, and young adult cancers runs the gamut from identifying oncogenic drivers and studying malignant transformation to designing clinical trials.

https://www.rockefeller.edu/our-scientists/heads-of-laboratories/905-sanford-m-simon/

17. **Memorial Sloan Kettering Cancer Center, New York, USA**

Sloan Kettering Institute and Department of Pediatrics, Departments of Pediatrics

Alex Kentsis

kentsisa@mskcc.org

Functional Proteomics and Molecular Pharmacology.

https://alexkentsis.net/

18. **Memorial Sloan Kettering Cancer Center, New York, USA**

Immune Discovery and Monitoring Service

Jaap Jan Boelens

boelensj@mskcc.org

Bone marrow and cord blood transplantation to treat blood diseases in children and young adults.

https://www.mskcc.org/cancer-care/doctors/jaap-jan-boelens

19. **Memorial Sloan Kettering Cancer Center, New York, USA**

Pediatric cancer

Andrew Kung

kunga@mskcc.org

The Andrew Kung laboratory focuses on identifying the causes of pediatric cancers and developing new treatments to benefit children and teens with these diseases.

https://www.mskcc.org/cancer-care/doctors/andrew-kung

20. **Memorial Sloan Kettering Cancer Center, New York, USA**

Immuno-Oncology Program

Christopher Klebanoff

klebanoc@mskcc.org

The Klebanoff laboratory aims to overcome the key barriers limiting the success of adoptive T cell transfer (ACT) in solid tumors.

https://www.mskcc.org/research-areas/labs/christopher-klebanoff

21. **Memorial Sloan Kettering Cancer Center, New York, USA**

Human Oncology & Pathogenesis Program

Mark Ladanyi

ladanyim@mskcc.org

The Marc Ladayi laboratory focuses on the genomics and molecular pathogenesis of sarcomas and thoracic malignancies, with an emphasis on clinical translation of potential diagnostic markers and therapeutic targets.

https://www.mskcc.org/research-areas/labs/marc-ladanyi

22. **University College London (UCL), London, UK**

Pereira/Acedo Group

Pilar Acedo

p.nunez@ucl.ac.uk

Pancreatic cancer, cholangiocarcinoma, early detection, spatial biology, biomarkers, translational medicine, patient-derived models and photodynamic therapy.

https://www.ucl.ac.uk/medical-sciences/divisions/medicine/research/liver-and-pancreaticobiliary-cancer

23. **University Hospital Essen, Essen, Germany**

Translational Genomics, Dept. Ophthalmology

Samuel Peña-Llopis

Samuel.Pena-Llopis@uk-essen.de

Targeting the Vulnerabilities of Aggressive Tumors with BAP1 Mutations and Preclinical Validation with Patient-Derived Organoids.

https://www.uni-due.de/zmb/members/samuel-pena-llopis.php

24. Centre for Immuno-Oncology, Oxford, UK

Cancer Immunology

Felipe Galvez-Cancino

felipe.galvez-cancino@immonc.ox.ac.uk

Felipe Galvez-Cancino laboratory aims to define fundamental mechanisms that control anti-tumour immune responses, with the ultimate goal of developing novel therapeutics that impact patients and their families.

https://www.immonc.ox.ac.uk/team/felipe-galvez-cancino

25. Sir William Dunn School of Pathology, University of Oxford, Oxford, UK

Regulation of Mitotic Progression and Chromosome Segregation

Ulrike Gruneberg

ulrike.gruneberg@path.ox.ac.uk

Fundamental processes of cell division and their implications for human health.

https://www.path.ox.ac.uk/research-group/ulrike-gruneberg/

26. Department of Oncology/OxCIO, Oxford, UK

The Parkes lab

Eileen Parkes

Eileen.parkes@oncology.ox.ac.uk

The tumour microenvironment of chromosomally unstable cancers.

https://www.immonc.ox.ac.uk/research-groups/parkes-group

27. Departments of Chemistry and Pharmacology, University Oxford, Oxford, UK

Angela J. Russell

angela.russell@chem.ox.ac.uk

Cancer medicinal chemistry - specifically targeting hard-to-drug transcription factor complexes and cancer stem cell differentiation agents.

https://russellchem.web.ox.ac.uk/home

28. The Botnar Institute, Oxford, UK

Soft Tissue Biology Group

Sarah Snelling

sarah.snelling@ndorms.ox.ac.uk

Prognostics and Diagnostics for early treatment of Sarcoma.

https://www.ndorms.ox.ac.uk/research/research-groups/snelling

29. **Department of Oncology, University of Oxford, Oxford, UK**

T cell immunity and immunosuppression in cancer

Jie Yang

jie.yang@oncology.ox.ac.uk

The Jie Yang laboratory aims to uncover the molecular and cellular mechanisms underpinning immune regulation and cancer immunosuppression, with the goal of developing new approaches for cancer prevention and treatment of metastatic disease.

https://www.oncology.ox.ac.uk/team/jie-yang

30. **Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK**

Translational Neurooncology - Emerging Technologies for Analysis of the Brain

Olaf Ansorge

olaf.ansorge@ndcn.ox.ac.uk / casmir.turnquist@ndcn.ox.ac.uk

Their work focuses on three cutting-edge areas: rapid near-patient epigenomic and genomic diagnostics using Oxford Nanopore long-read sequencing (including liquid biopsies) to deliver integrated diagnoses within hours; in-depth characterisation of immune responses in selected gliomas, and an innovative cancer neuroscience programme to study, in real time, how glioma cells interact with neurons and respond to therapeutic interventions.

31. **El Colegio de la Frontera Sur, Unidad San Cristóbal, Chiapas, Mexico**

Grupo Académico de Enfermedades Emergentes, Epidémicas y del Metabolismo Asociadas a la Alimentación (EEEMAA)

Rosario García Miranda

rgarcia@ecosur.mx

Studies on cancer in women and its relationship with the gut microbiota.

32. **Institute for Research in Biomedicine, Bellinzona, Switzerland**

Infection and Immunity

Santiago F. González

santiago.gonzalez@irb.usi.ch

Their research integrates basic immunology with disease models to understand how immune responses—particularly inflammation and tumor–immune interactions—drive melanoma metastasis and cancer progression, with the goal of informing the development of new immunotherapies.

https://irb.usi.ch/irb-people/gonzalez-f-santiago/?id=9000

33. Université de Lausanne, Lausanne, Switzerland

Laboratory of Regenerative Hematopoiesis

Olaia Naveiras

olaia.naveiras@unil.ch

The Olaia Naveiras laboratory focuses on understanding and modulating the bone marrow microenvironment to improve blood progenitor function in malignant hematopoiesis, aging, and bone marrow failure.

https://wp.unil.ch/naveiras-lab/team/

34. Université de Lausanne, Lausanne, Switzerland

Center for Integrative Genomics

Lluís Fajas Coll

lluis.fajas@unil.ch

Their research explores the interplay between cell cycle regulation, metabolism, and cancer, investigating how pathways such as Cdk4–Rb–E2F1 reprogram tumor cell metabolism and promote proliferation and survival, with implications for the identification of new therapeutic targets in cancer.

https://www.unil.ch/fbm/en/home/menuinst/recherche/ssf/cig/recherche/fajas-coll.html

35. The Francis Crick Institute, London, UK

Cancer Macroenvironment Lab

Jose M. Adrover

jose.adrover@crick.ac.uk

Adrover's laboratory studies how cancer affects the entire body, with an emphasis on blood cell formation and the cardiovascular and immune systems.

https://www.crick.ac.uk/research/find-a-researcher/jose-m-adrover

36. Paris Brain Institute, Paris, France

Neuro-oncology Lab

Mehdi Touat

mehdi.touat@aphp.fr / franck.bielle@aphp.fr

Their multidisciplinary team studies brain tumor evolution, mechanisms of resistance to treatments and strategies to overcome them, as well as interactions between brain tumors and the immune system.

https://parisbraininstitute.org/collaborators/touat-mehdi

37. Nuffield Department of Population Health, University of Oxford, Oxford, UK

Predicting and understanding risk of common cancers

Christiana Kartsonaki
christiana.kartsonaki@ndph.ox.ac.uk

Evaluating risk prediction models for common cancers, including breast, ovarian, endometrial, colorectal, and lung, extending and developing models in diverse large-scale prospective cohort studies; Associations of risk factors, including genetics, lifestyle, infectious pathogens, proteomics, and metabolomics with risk of cancer.
Christiana Kartsonaki — Nuffield Department of Population Health

38. **The MRC Weatherall Institute of Molecular Medicine (MRC WIMM), University of Oxford, Oxford, UK**

Understanding mutations in blood cancer.

Doug Higgs and Mira Kassouf
Doug.higgs@imm.ox.ac.uk
Mira.kassouf@imm.ox.ac.uk

This study aims to elucidate how a specific combination of mutations in key blood cancer–associated genes disrupt downstream gene regulation and impair normal differentiation, using a rare cohort of 138 patients with myelodysplastic syndrome associated with alpha thalassaemia (ATMDS).
https://www.imm.ox.ac.uk/people/doug-higgs
https://www.rdm.ox.ac.uk/people/mira-kassouf